According to a recent LinkedIn post from ABM Respiratory Care, the company plans to participate in the Oklahoma University Health Respiratory Conference in Oklahoma City on Friday, February 27. The post highlights in-person demonstrations of its BiWaze platform, including BiWaze Cough and BiWaze Clear airway clearance systems, led by a company representative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests a focus on showcasing technical features such as a dual blower system for bi-directional control of inhalation and exhalation, and a closed breathing circuit aimed at supporting mucus mobilization and aerosol deposition. For investors, this emphasis on clinical functionality and conference engagement may indicate ongoing efforts to drive clinician adoption, expand hospital-to-home use cases, and support future revenue growth in the respiratory care segment.
The post also references new clinical studies related to the BiWaze platform, implying that ABM Respiratory Care is seeking to strengthen the evidence base behind its products. If these studies translate into favorable clinical outcomes and guideline alignment, they could enhance the company’s competitive positioning with hospital systems and respiratory therapists, potentially improving pricing power and contract opportunities.
By directing non-attendees to online resources and demo scheduling links, the post indicates a parallel digital outreach strategy alongside in-person events. This hybrid approach could help ABM Respiratory Care scale its commercial funnel, deepen engagement with key decision-makers in respiratory care, and support longer-term commercialization of its airway clearance portfolio.